U.S. Patent and Trademark Office, U.S. DEPARTNEN! U.S. Patent and Trademark Office, U.S. DEPARTNEN! Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid Ok

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10711385			
Filing Date		2004-09-15			
First Named Inventor	Bogd	Bogdan Radu			
Art Unit		2837			
Examiner Name	Michael A. Friedhofer				
Attorney Docket Numb	or	MASI -58			

					U.S.	PATENTS			Remove		
Examiner Initial*	Cite No			Kind Code ¹ Issue Date		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	4104555	A	1978-0	8-01	Fleming					
If you wisl	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	lease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date		Name of Pate of cited Docu	entee or Applicant ment	Releva		Lines where ges or Relev	
	1	20050140167	A1	2005-0	6-30	Jaggi					
If you wis	h to a	dd additional U.S. Publi		p		, , , , , , , , , , , , , , , , , , , ,		d button	$\overline{}$		
				FOREIG	SN PAT	TENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i		Kind Code4	Publication Date	Applicant of cited		vhere Rel	or Relevant	+4
	1	1110822	EP		B1	2004-07-21	Peter Jansen et al				
	2	03101779	wo		A2	2003-12-11	Johnson Controls Technology Comp	any			
	3	9086273	JP			1997-03-31	Mazda Molor				

| INFORMATION DISCLOSURE | Application Number | 10711395 | Filing Date | 10711395 | Filing Date | 2004-406-15 | Fi

Examiner (Initials* N	Total No include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journals, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							
	1	MAKIYA, DAVID J. (EXAMINER), United States Patent and Trademark Office, Office Acton mailed May 9, 2006 in related Application No. 10/711,462						
:	2	GERMAN PATENT OFFICE, Office Action mailed May 5, 2006 in corresponding German Application No. 10 2005 043 901.2-42						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered

See Kind Codes of USPTO Plantin Documents at year, USPTO_DOV_or MPEP 901.04. * Enter office an all assed the document, by the to-elect code (WIPO Standard ST3.). **Explainase plant of comment, be radication to the year of the reign or the Engerer must proceed the senial number of the plant document.
**India of coursent by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. **Applicant is to plant a check mark here if the plantin document is proceed to the plantin document to the plantin and the p

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10711385		
	Filing Date		2004-09-15		
	First Named Inventor	Bogd	an Radu		
Art Unit			2837		
	Examiner Name	Micha	chael A. Friedhofer		
	Attorney Docket Number		MASL-58		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s);

That each item of information contained in the information disclosure statement was first cited in any communication of form a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information siclosure statement. See 37 CFR 197(a)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart to reign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c)(c)

- 7 See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☐ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/William R. Allen/	Date (YYYY-MM-DD)	2006-05-22			
Name/Print	William R. Allen	Registration Number	48389			

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenan's Afford, U.S. Department of Commence, P. 0. Bot 1450, Alexandria, V.3.251.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.